SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aduro BioTech, Inc. (ADRO)

NEW YORK, May 16, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Aduro BioTech, Inc. ("Aduro" or the "Company") (NASDAQ: ADRO).  Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484. 

The investigation concerns whether Aduro and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 16, 2016, pre-market, the Aduro revealed that its pancreatic cancer drug missed the main endpoint in a Phase 2b clinical trial. The CRS-207 therapy that was tested both alone and in combination with GVAX Pancreas and was proposed for patients with cancer who had ineffectively undergone two prior metastatic treatments.  Aduro chairman, Stephen Isaacs, said the discoveries were "unexpected" given "the divergence of these data from the results of our Phase 2a study."  Aduro also said that the therapies are continuously being tested in an ongoing trial to serve as a second-line treatment for patients with metastatic pancreatic cancer.  Following this news, Aduro stock dropped as much as $3.43 per share, or 32%, to a low of $7.26 during intraday trading on May 16, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Aduro, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!adro/kitmf. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-aduro-biotech-inc-adro-300269191.html

SOURCE Bronstein, Gewirtz & Grossman, LLC